Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場2017-2021

◆タイトル:Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021
◆商品コード:IRTNTR11320
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年12月29日
◆ページ数:77
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場規模及び予測、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About CINV Drugs
The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics’ SUSTOL and Tesaro’s VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.

Technavio’s analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck
• Tesaro

[Other prominent vendors]
• Acacia Pharma
• Aphios
• Baxter Healthcare
• Dr. Reddy’s Laboratories
• Eisai
• Especificos Stendhal
• F. Hoffmann-La Roche
• Kyowa Hakko Kirin
• Lee’s Pharmaceutical Holdings
• Midatech Pharma
• Mundipharma
• Mylan
• Ono Pharmaceutical
• OPKO Health
• Orchid Chemicals & Pharmaceuticals
• Otsuka Pharmaceutical
• Purdue Pharma
• Sandoz (a subsidiary of Novartis)
• SciClone Pharmaceuticals
• Shin Nippon Biomedical Laboratories
• Solasia Pharma K.K.
• Specialised Therapeutics
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals

[Market driver]
• Growing preference of chemotherapy drugs in developing countries
• For a full, detailed list, view our report

[Market challenge]
• Growing popularity of alternate therapies for the treatment of cancer in developed countries
• For a full, detailed list, view our report

[Market trend]
• Increasing inorganic growth strategies likely to fuel the market growth
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Disease overview
• Understanding the disease
• Pathophysiology
• Central pathway
• Peripheral pathway
• Management of disease

PART 06: Pipeline analysis

PART 07: Market landscape
• Global CINV drugs market
• Five forces analysis

PART 08: Market segmentation by therapy
• Serotonin receptor antagonists
• NK1 receptor antoagonists
• Others

PART 09: Geographical segmentation
• CINV drugs market in Americas
• CINV drugs market in EMEA
• CINV drugs market in APAC

PART 10: Market drivers
• Growing cancer population driving the market growth
• Growing preference for chemotherapy drugs in developing countries
• Approval of new drugs fuels the market growth

PART 11: Impact of drivers

PART 12: Market challenges
• Growing popularity of alternate therapies for the treatment of cancer in developed countries
• Loss of patent exclusivities increasing generic competition
• Limitations in existing therapies hindering the growth prospects

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Robust R&D activities fueling the pipeline
• Increasing inorganic growth strategies likely to fuel the market growth
• Novel treatment options coupled with new applications

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck
• Tesaro
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Pipeline landscape
Exhibit 03: Key pipeline candidates
Exhibit 04: Global CINV drugs market snapshot
Exhibit 05: Analysis of global CINV drugs market
Exhibit 06: Global CINV drugs market 2016-2021 ($ billions)
Exhibit 07: Key initiatives in emerging economies
Exhibit 08: Opportunity analysis of global CINV drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by therapy 2016 (% share)
Exhibit 12: Lifecycle analysis of segments in global CINV drugs market
Exhibit 13: Geographic segmentation by revenue 2016 and 2021
Exhibit 14: Geographic segmentation by revenue 2016 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: CINV drugs market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: CINV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: CINV drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Key drivers and challenges in APAC
Exhibit 22: Top ten cancers in the US in 2013
Exhibit 23: Key approvals in the market in 2015 and 2016
Exhibit 24: Impact of drivers
Exhibit 25: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 26: Forcefield analysis of drivers and challenges
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Key vendors that are extensively conducting R&D activities
Exhibit 29: Competitive structure analysis of global CINV drugs market 2015
Exhibit 30: Market share analysis in global CINV drugs market
Exhibit 31: Competitive analysis of global CINV drugs market
Exhibit 32: Market penetration of various global CINV drugs manufacturers 2015
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Helsinn: Key highlights
Exhibit 37: Helsinn: Strength assessment
Exhibit 38: Helsinn: Strategy assessment
Exhibit 39: Helsinn: Opportunity assessment
Exhibit 40: Heron Therapeutics: Key highlights
Exhibit 41: Heron Therapeutics: Strength assessment
Exhibit 42: Heron Therapeutics strategy assessment
Exhibit 43: Heron Therapeutics: Opportunity assessment
Exhibit 44: Merck: Key highlights
Exhibit 45: Merck: strength assessment
Exhibit 46: Merck: Strategy assessment
Exhibit 47: Merck: Opportunity assessment
Exhibit 48: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
Exhibit 49: Tesaro: Key highlights
Exhibit 50: Tesaro: Strength assessment
Exhibit 51: Tesaro: Strategy assessment
Exhibit 52: Tesaro: Opportunity assessment



【掲載企業】

GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, Acacia Pharma, Aphios, Baxter Healthcare, Dr. Reddy's Laboratories, Eisai, Especificos Stendhal, F. Hoffmann-La Roche, Kyowa Hakko Kirin, Lee’s Pharmaceutical Holdings, Midatech Pharma, Mundipharma, Mylan, Ono Pharmaceutical, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical, Purdue Pharma, Sandoz (a subsidiary of Novartis), SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma K.K., Specialised Therapeutics, Sun Pharma, Taiho Pharmaceutical, Teva Pharmaceuticals.

【資料のキーワード】

がん化学療法による悪心・嘔吐、CINV治療薬、セロトニン受容体遮断薬、NK1受容体遮断薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場2017-2021] (Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021 / IRTNTR11320)販売に関する免責事項
[がん化学療法による悪心・嘔吐(CINV)治療薬の世界市場2017-2021] (Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021 / IRTNTR11320)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆